

No	Reference Number	IRAS No	Title	Target number of patients agreed?	Target range minimum	Target range maximum	Target date to recruit patients agreed?	Date Agreed to Recruit Target No of Patients	Total no of patients recruited at the agreed target date	Date Trial Closed to Recruitment	Total Number of Study Participants Recruited	Reason for closure of trial
1	14/LO/2182	143226	STOP-HCC TS-103 A phase 3 clinical trial of intra-arterial TheraSphere in the treatment of patients with unresectable hepatocellular carcinoma	Number Agreed	2	2	Date Agreed	15/01/2018	6	04/09/2017	6	Recruitment Finished
2	15/WM/0056	159740	Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit	Range Agreed	35	60	Date Agreed	24/02/2018	54	24/02/2018	54	Recruitment Finished
3	14/YH/1141	161305	A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy	Number Agreed	2	2	Date Agreed	15/03/2018	2	30/11/2017	2	Withdrawn By Sponsor
4	15/WM/0327	185434	Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) system for pulmonary artery denervation in patients with pulmonary hypertension. (TROPHY)	Range Agreed	1	5	Date Agreed	30/09/2017	6	14/09/2017	6	Recruitment Finished
5	15/NW/0868	188121	A Phase 3 study of Efficacy, Safety and Tolerability of Chronocort® compared with Standard Glucocorticoid Replacement Therapy in the treatment of Congenital Adrenal Hyperplasia	Number Agreed	7	7	Date Agreed	31/01/2018	10	31/01/2018	10	Recruitment Finished
6	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster des system in unselected patients representing everyday clinical practice.	Number Agreed	50	50	Date Agreed	31/05/2018	222	03/05/2018	222	Recruitment Finished
7	14/LO/2156	166004	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis	Range Agreed	10	15	Date Agreed	19/10/2017	10	31/07/2017	10	Recruitment Finished
8	15/LO/0545	172357	Clinical and device functional Assessment of Real world ICD pAtients - CARAT	Number Agreed	10	10	Date Agreed	31/10/2017	10	31/10/2017	10	Recruitment Finished
9	16/EE/0011	194393	A prospective, randomized, double blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of oto-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease.	Number Agreed	3	3	Date Agreed	30/11/2017	9	20/07/2017	9	Recruitment Finished

10	15/EE/0418	188945	CheckMate 451 – A randomised, multicentre, double-blind, Phase 3 study of Nivolumab, Nivolumab in combination with Ipilimumab, or placebo as maintenance therapy in subjects with extensive-stage disease small cell lung cancer (ED-SCLC) after completion of platinum-based first line chemotherapy	Range Agreed	2	4	Date Agreed	30/10/2019	3	08/09/2017	3	Recruitment Finished
11	16/YH/0454	211679	A prospective multi-centre observational study to evaluate the capabilities of a portable magnetocardiograph (MCG) device to rule-out acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain symptoms consistent with ACS.	Number Agreed	175	175	Date Agreed	30/04/2018	175	30/04/2018	175	Recruitment Finished
12	16/EM/0278	208188	A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia.	Range Agreed	1	7	Date Agreed	12/03/2018	10	12/03/2018	10	Recruitment Finished
13	16/EE/0235	202344	A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment	Range Agreed	3	4	Date Agreed	31/10/2017	6	21/09/2017	6	Recruitment Finished
14	16/LO/1697	212844	A Phase III randomised, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma.	Number Agreed	3	3	Date Agreed	30/04/2018	4	31/05/2018	4	Recruitment Finished
15	16/EE/0243	207331	A 6-month, multicenter, Phase 3, open-label extension safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease	Number Agreed	5	5	Date Agreed	30/06/2017	12	05/09/2017	12	Recruitment Finished
16	16/WM/0359	211812	A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma.	Range Agreed	2	5	Date Agreed	30/05/2020	4	16/01/2018	4	Recruitment Finished

17	16/YH/0450	213782	20150288: A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)	Range Agreed	2	5	Date Agreed	30/06/2018	5	04/05/2018	5	Recruitment Finished
18	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.	Range Agreed	4	21	Date Agreed	01/05/2019	19	13/12/2017	19	Recruitment Finished
19	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	Number Agreed	4	4	Date Agreed	27/10/2017	4	16/10/2017	4	Recruitment Finished
20	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu® and No Drains (test) in Mastectomy.	Number Agreed	2	2	Date Agreed	29/09/2017	5	29/09/2017	5	Recruitment Finished
21	12/YH/0498	102641	An Open, Phase I, Exploratory Study of MTL-005 Radiosensitization in Patients With Advanced Carcinoma of the Head and Neck: Part 1 to Evaluate Safety in a Dose Escalation Design in Patients Indicated for Palliative Radiotherapy, Part 2 to Evaluate Safety and Efficacy in a Dose-Escalation Design in Patients Indicated for Cisplatin Chemoradiotherapy - MOREX	Number Agreed	7	7	Date Agreed	20/03/2018	4	20/03/2018	4	Recruitment Finished
22	15/LO/0337	171675	A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension	Number Agreed	2	3	Date Agreed	31/08/2017	0	31/08/2017	0	Recruitment Finished
23	14/WS/1146	166537	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)	Number Agreed	20	20	Date Agreed	30/09/2017	12	20/09/2017	12	Recruitment Finished
24	15/LO/1425	184843	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis.	Number Agreed	2	2	Date Agreed	31/10/2017	0	13/10/2017	0	Withdrawn by Sponsor

25	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures - CARD 3867 VOYAGER PAD	Range Agreed	20	40	Date Agreed	31/01/2018	6	08/12/2017	6	Recruitment Finished
26	15/NW/0592	185435	A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function.	Number Agreed	3	3	Date Agreed	11/08/2017	2	11/08/2017	2	Recruitment Finished
27	16/NW/0218	173712	A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to severe COPD	Number Agreed	6	6	Date Agreed	30/09/2017	4	11/08/2017	4	Recruitment Finished
28	16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Number Agreed	5	5	Date Agreed	16/11/2017	3	16/11/2017	3	Recruitment Finished
29	15/EM/0179	177000	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low Ejection Fraction UNTOUCHED	Range Agreed	7	50	Date Agreed	31/12/2019	6	27/02/2018	6	Recruitment Finished
30	16/YH/0186	200765	A phase 4 double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety and tolerability of mirabegron in men with overactive bladder (OAB) symptoms while taking the alpha-blocker tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).	Number Agreed	8	8	Date Agreed	18/04/2018	0	18/04/2018	0	Recruitment Finished
31	16/EE/0040	196164	A Phase IB, Blinded, Randomized, Multicenter, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients with Non Healing Neuropathic Diabetic Foot Ulcers.	Number Agreed	1	1	Date Agreed	24/02/2018	0	08/01/2018	0	Recruitment Finished
32	16/LO/1138	207606	A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD).	Number Agreed	1	1	Date Agreed	30/11/2018	0	17/01/2018	0	Withdrawn By Sponsor

33	16/EM/0320	208246	A Randomized, Multicentre, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab and Taxane Base Therapy [KATE-2]	Number Agreed	2	2	Date Agreed	04/07/2017	1	07/08/2017	1	Recruitment Finished
34	16/EM/0279	208089	PIONEER-5: Efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 diabetes and moderate renal impairment.	Number Agreed	5	5	Date Agreed	29/09/2017	3	29/09/2017	3	Recruitment finished
35	16/EM/0376	211430	A 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with interstitial cystitis/bladder pain syndrome followed by a 2-arm, 14 or 40 week open label extension	Number Agreed	4	4	Date Agreed	31/03/2018	1	15/02/2018	1	Recruitment Finished
36	16/NW/0606	211110	A Phase II single-arm, open-label monotherapy clinical trial of Pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (KEYNOTE-427)	Number Agreed	4	4	Date Agreed	20/03/2020	0	24/04/2018	0	Recrutimetn finished
37	16/EM/0384	182787	CV 185316: An Open-label, 2x2 Fractorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	Number Agreed	8	8	Date Agreed	31/05/2018	4	10/04/2018	4	Recruitment Finished
38	17/NE/0115	218417	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	Range Agreed	3	4	Date Agreed	23/04/2018	1	26/04/2018	1	Withdrawn By Host
39	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	4	4	Date Agreed	31/08/2018	0	27/04/2018	0	Withdrawn by Sponsor
40	16/YH/0506	212039	A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	Number Agreed	2	2	Date Agreed	22/12/2017	1	30/11/2017	1	Recruitment Finished
41	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2	Number Agreed	6	6	Date Agreed	30/03/2018	0	05/04/2018	0	Withdrawn by Sponsor

42	17/LO/1147	222154	A Randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy	Number Agreed	6	6	Date Agreed	31/05/2018	4	23/03/2018	4	Recruitment Finished
43	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent patients with Atypical Hemolytic Uremic Syndrome (aHUS)	Range Agreed	0	1	Date Agreed	31/12/2018	0	25/05/2018	0	Recruitment Finished
44	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	Number Agreed	4	4	Date Agreed	31/05/2018	0	27/04/2018	0	Recruitment Finished